Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Filiz Yucebay
Institution:
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Observed institutions:
Nebraska Medical Center,
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute,
The Ohio State University Wexner Medical Center,
Northwestern Memorial Hospital,
The Ohio State University
ORCID:
0000-0002-6861-3546
Observed ORCID:
0000-0002-6861-3546
OpenAlex ID:
A5049820205
Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions
2019
·
Suzanne Cole
, Matthew Zibelman
, et al.
·
American Society of Clinical Oncology Educational Book
·
31
Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience
2019
·
Filiz Yucebay
, Christina Matthews
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
23
Development and Implementation of an Oral Oncology Drug Repository Program
2020
·
Lauren Stanz
, Tim Ulbrich
, et al.
·
JCO Oncology Practice
·
14
Intrathecal Chemotherapy: An Alternative Treatment Strategy to Prolonged Corticosteroids for Severe CAR T Associated Neurotoxicity
2020
·
Filiz Yucebay
, Joseph Maakaron
, et al.
·
Transplantation and Cellular Therapy
·
14
Use of organism identification by 16S ribosomal RNA polymerase chain reaction to shorten antimicrobial length of therapy
2017
·
Elise M. Gilbert
, Filiz Yucebay
, et al.
·
Diagnostic Microbiology and Infectious Disease
·
8
Student Preparation for PGY1 Residency Training by US Colleges of Pharmacy: Survey of the Residency Program Director Perspective
2017
·
Alyssa B. Mutz
, Jacob Beyer
, et al.
·
Hospital Pharmacy
·
5
CAR T-Cell Therapy: Clinical Outcomes, Patient Selection and Financial Metrics with Tisagenlecleucel and Axicabtagene Ciloleucel, a Single Center Experience
2020
·
Nathan Denlinger
, Zachary Braunstein
, et al.
·
Transplantation and Cellular Therapy
·
4
PDF
Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
2022
·
Abdullah M. Khan
, Filiz Yucebay
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
2
Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma
2020
·
Filiz Yucebay
, Ashleigh Keiter
, et al.
·
Blood
·
2
ABCL-509 Healthcare Utilization and Costs in Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma
2022
·
Nathan Denlinger
, Ying Huang
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Poster: ABCL-509 Healthcare Utilization and Costs in Chimeric Antigen Receptor T-Cell Therapy for B-cell Lymphoma
2022
·
Nathan Denlinger
, Ying Huang
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Efficacy of Once-Weekly Bortezomib with Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma
2018
·
Natalia Gut
, Filiz Yucebay
, et al.
·
Blood
Use of Organism Identification by 16S Ribosomal RNA Polymerase Chain Reaction to Shorten Antimicrobial Length of Therapy
2015
·
Filiz Yucebay
, Elise Gilbert
, et al.
·
Open Forum Infectious Diseases
Show more works
View as search
Works count:
13
Citation count:
104
H-index:
5
I10-index:
4
Year
Topic
Type